Summary
In a previous report it was suggested that the total body clearance of mitomycin C (MMC) was different after single agent treatment compared to combination chemotherapy. This suggestion was based on recalculations to one dose level. In the present study a fixed dose of 10 mg/m2 was used. Seven patients on single agent MMC and eight on combination chemotherapy were studied. Terminal half-life varied from 25 to 78 mm, volume of distribution from 7 to 73 l/m2, total body clearance from 11 to 56 l/h per m2, and area under the plasma concentration-time curve (AUC) from 177 to 933 μg/h per 1. Total body clearance was significantly higher and AUC significantly lower in patients on combination chemotherapy. The cause of this difference was not investigated.
This is a preview of subscription content, log in via an institution to check access.
References
Buice RG, Niell HB, Sidhu P, Gurley BJ (1984) Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. Cancer Chemother Pharmacol 13:1–4
Doll DC, Weiss RB, Issell BF (1985) Mitomycin: ten years after approval for marketing J Clin Oncol 3:276–286
den Hartigh J, van Oort WJ, Bocken MCYM, Pinedo HM (1981) High performance liquid chromatography determination of the antitumor agent mitomycin C in human blood plasma. Anal Chim Acta 127:47–53
den Hartigh J, McVie JG, van Oort WJ, Pinedo HM (1983) Pharmacokinetics of mitomycin C in humans Cancer Res 43:5017–5021
den Hartigh J, Voortman G, van Oort WJ, Pinedo HM, Weenen H (1983) Binding of mitomycin C to red blood cells and plasma proteins. Proc ECCO 2:15
van Hazel GA, Scott M, Rubin J (1983) Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 67:805–810
Hu E, Howell SB (1983) Pharmacokinetics of intraarterial mitomycin C in humans Cancer Res 43:4474–4477
Kerpel Fronius S, Verweij J, Stuurman M, Lelieveld, P, Pinedo HM (1986) Pharmacokinetics of mitomycin C given to Wistar rats alone in combination or after induction of microsomal drug metabolism (in press)
Schilcher RB, Young JD, Ratanatharathorn V, Karanes C, Baker LH (1984) Clinical pharmacokinetics of high dose mitomycin C. Cancer Chemother Pharmacol 13:186–198
Verweij J, Boven E, van der Meulen J, Pinedo HM (1984) Recovery from mitomycin C induced haemolytic uraemic syndrome. A case report. Cancer 54:2878–2881
Wakaki S, Marumo H, Tomioka K (1958) Isolation of new fractions of antitumor mitomycins. Antibiot Chemother 8:228–240
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verweij, J., Stuurman, M., de Vries, J. et al. The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy. J Cancer Res Clin Oncol 112, 283–284 (1986). https://doi.org/10.1007/BF00395925
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00395925